EXHIBIT 99.2

                                 NEWS RELEASE


OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE FILING OF A SUPPLEMENTAL NEW DRUG
APPLICATION TO THE FDA FOR TARCEVA(TM) IN PANCREATIC CANCER

         MELVILLE, N.Y. and SOUTH SAN FRANCISCO, Calif.--May 2, 2005--OSI
Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced
today that OSI submitted a supplemental New Drug Application (sNDA) with the
U.S. Food and Drug Administration (FDA) for use of Tarceva(TM) (erlotinib) plus
gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in
patients who have not received any previous treatment. Tarceva is the first drug
to significantly improve survival in a Phase III trial when added to gemcitabine
chemotherapy in first-line pancreatic cancer compared to gemcitabine alone.

         "There is an urgent need for additional therapeutic options for
patients with advanced pancreatic cancer and we look forward to working closely
with the FDA through this review process," stated Colin Goddard, Ph.D., Chief
Executive Officer of OSI Pharmaceuticals.

         "Pancreatic cancer is difficult to treat and is a disease in which only
20 percent of patients survive one year after diagnosis. The improved survival
observed in the Phase III trial that is the basis for this filing represents a
potential treatment advance for both patients and physicians," said Hal Barron,
M.D., Genentech's senior vice president of Development and chief medical
officer. "We would like to recognize our colleagues at OSI Pharmaceuticals for
their hard work on this important filing."

         The sNDA filing is based on a pivotal Phase III multi-center,
randomized, double-blind, placebo-controlled trial evaluating Tarceva in
patients with locally advanced or metastatic pancreatic cancer. Results of the
trial were presented in January at the Second Annual Gastrointestinal Cancers
Symposium in Hollywood, Fla. A total of 569 patients were randomized in the
study, to receive Tarceva plus gemcitabine or gemcitabine plus placebo.

         The study demonstrated a statistically significant 23.5 percent
improvement in overall survival for patients receiving Tarceva plus gemcitabine
compared to patients receiving gemcitabine plus placebo. Twenty-four percent of
patients receiving Tarceva plus gemcitabine were alive after one year compared
to 17 percent of patients receiving gemcitabine plus placebo. Median survival in
the Tarceva plus gemcitabine arm was 6.4 months compared to 5.9 months in the
gemcitabine plus placebo arm. An exploratory analysis of survival by
pre-treatment characteristics also showed that patients with metastatic disease
and patients with poor





performance status derived a significant survival benefit. Progression-free
survival in the Tarceva plus gemcitabine arm also was significantly improved,
although there was virtually no difference in tumor response (9 percent in
patients receiving Tarceva plus gemcitabine versus 8 percent in the gemcitabine
plus placebo arm).

         The analysis of safety data did not reveal any unexpected safety
signals beyond that seen in previous studies of Tarceva in both monotherapy and
combination settings. As expected, rash and diarrhea were the principal Tarceva
related side effects seen in the study. Rash was reported by 72 percent of
patients who received Tarceva plus gemcitabine and by 28 percent of patients who
received gemcitabine plus placebo. Diarrhea was reported by 51 percent of
patients who received Tarceva plus gemcitabine and by 36 percent of patients who
received gemcitabine plus placebo. Possible interstitial lung disease (ILD) was
experienced by 2.1 percent of patients in the Tarceva plus gemcitabine arm
compared with 0.4 percent in the gemcitabine plus placebo arm. These ILD
incidence levels for the combination of Tarceva and gemcitabine were higher than
the 0.8 percent incidence reported for both monotherapy Tarceva and placebo in
the pivotal BR.21 study in advanced NSCLC. However, the incidence of possible
ILD from all clinical studies with Tarceva is 0.7 percent.

         About Pancreatic Cancer

         According to the World Health Organization, more than 216,000 people
worldwide are diagnosed each year with pancreatic cancer. The American Cancer
Society estimates that in 2005 approximately 32,180 people in the United States
will be diagnosed with pancreatic cancer and approximately 31,800 will die of
the disease. Most pancreatic tumors originate in the exocrine duct cells or in
the cells that produce digestive enzymes (acinar cells). Called adenocarcinomas,
these tumors account for nearly 95 percent of pancreatic cancers.

         About Tarceva

         Tarceva is currently approved by the FDA as a monotherapy for the
treatment of patients with locally advanced or metastatic non-small cell lung
cancer after failure of at least one prior chemotherapy regimen and is an oral
tablet indicated for daily administration. Results from two earlier large,
randomized, placebo-controlled clinical trials in first-line advanced NSCLC
patients showed no clinical benefit with concurrent administration of Tarceva
with doublet platinum-based chemotherapy (carboplatin and paclitaxel or
gemcitabine and cisplatin) and its use is not recommended in that setting.

         Tarceva is a small molecule designed to target the human epidermal
growth factor receptor 1 (HER1) pathway, which is one of the factors critical to
cell growth in a number of different cancer types. HER1, also known as EGFR, is
a component of the HER signaling pathway, which plays a role in the formation
and growth of numerous cancers. Tarceva is designed to inhibit the tyrosine
kinase activity of the HER1 signaling pathway inside the cell, which may block
tumor cell growth. Tarceva is the only EGFR therapy to show in a Phase III trial
improved survival for advanced NSCLC patients. Additional early-stage trials of
Tarceva are being conducted in other solid tumors.





         About Tarceva Safety

         In the pivotal NSCLC trial, the most common adverse reactions in
patients receiving Tarceva were rash and diarrhea. Severe grade 3/4 rash and
diarrhea occurred in nine and six percent of Tarceva-treated patients,
respectively. Rash and diarrhea each resulted in discontinuation of one percent
of Tarceva-treated patients. Dose reduction was needed for six and one percent
of patients for rash and diarrhea, respectively. Historically, there have been
infrequent reports of serious interstitial lung disease (ILD), including
fatalities, in patients receiving Tarceva for treatment of NSCLC or other
advanced solid tumors. In the Phase III trial, severe pulmonary reactions,
including potential cases of interstitial lung disease, were infrequent (0.8
percent) and were equally distributed between treatment arms. The overall
incidence of possible ILD in Tarceva-treated patients from all studies was
approximately 0.7 percent.

         About OSI Pharmaceuticals

         OSI Pharmaceuticals is a leading biotechnology company primarily
focused on the discovery, development and commercialization of high-quality
pharmaceutical products that extend life or improve the quality of life for
cancer and diabetes patients worldwide. OSI's primary business remains oncology,
but the Company has a second business interest in the area of diabetes through
its subsidiary, Prosidion Limited, based in the United Kingdom. Tarceva(TM)
(erlotinib), OSI's flagship product, is the first drug discovered and developed
by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated
the ability to improve survival in non-small cell lung cancer and pancreatic
cancer. OSI exclusively markets Novantrone(R) (mitoxantrone concentrate for
injection) for the approved oncology indications and markets Gelclair(R)
Bioadherent Oral Gel for the relief of pain associated with oral mucositis.

         About Genentech BioOncology

         Genentech is committed to changing the way cancer is treated by
establishing a broad oncology portfolio of innovative, targeted therapies with
the goal of improving patients' lives. The company is the leading provider of
anti-tumor therapeutics in the United States. Genentech is leading clinical
development programs for Rituxan(R) (Rituximab), Herceptin(R) (Trastuzumab),
Avastin(TM) (bevacizumab), and Tarceva(TM) (erlotinib), and markets all four
products in the United States, either alone (Avastin and Herceptin) or with
Biogen Idec Inc. (Rituxan) or OSI Pharmaceuticals, Inc. (Tarceva). Genentech has
licensed Rituxan, Herceptin, and Avastin, and OSI Pharmaceuticals has licensed
Tarceva to Roche for sale by the Roche Group outside of the United States.

         The company has a robust pipeline of potential oncology therapies with
a focus on four key areas: angiogenesis, apoptosis (i.e., programmed cell
death), the HER pathway, and B-cell biology. A therapeutic antibody directed at
the HER pathway is currently in Phase II trials and in early development are a
small molecule directed at the hedgehog pathway, a therapy targeting apoptosis,
and a humanized anti-CD20 antibody for hematology/oncology indications.





         Genentech is a leading biotechnology company that discovers, develops,
manufactures and commercializes biotherapeutics for significant unmet medical
needs. A considerable number of the currently approved biotechnology products
originated from, or are based on, Genentech science. Genentech manufactures and
commercializes multiple biotechnology products directly in the United States,
and receives royalties or other income from companies that are licensed to
market its products outside of the United States. The company has headquarters
in South San Francisco, California and is traded on the New York Stock Exchange
under the symbol DNA.

         Regarding OSI

         This news release contains forward-looking statements. These statements
are subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements made.
Factors that might cause such a difference include, among others, the completion
of clinical trials, the FDA review process and other governmental regulation,
OSI's and its collaborators' abilities to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, the ability to
effectively market products, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.

         For full prescribing information, including Boxed Warnings for Avastin,
Rituxan and Herceptin, or for Tarceva full prescribing information, please call
800-821-8590.

         CONTACT: OSI Contact:
         Kathy Galante, 631-962-2000
                  or
         Genentech Media Contact:
         Kristina Becker, 650-467-6450
                  or
         Genentech Investor Contact:
         Kathee Littrell, 650-225-1034